Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection
Status:
Terminated
Trial end date:
2021-05-19
Target enrollment:
Participant gender:
Summary
The study aims to assess the potential benefit and evaluate the safety and tolerability of a
single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented infection
of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary involvement.
Subjects will be administered a single dose of VIB7734 injected under the skin, assessed for
efficacy for 28 days and followed for an additional 42 days.